Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration.

Abstract

mTOR inhibition is beneficial in neurodegenerative disease models and its effects are often attributable to the modulation of autophagy and anti-apoptosis. Here, we report a neglected but important bioenergetic effect of mTOR inhibition in neurons. mTOR inhibition by rapamycin significantly preserves neuronal ATP levels, particularly when oxidative phosphorylation is impaired, such as in neurons treated with mitochondrial inhibitors, or in neurons derived from maternally inherited Leigh syndrome (MILS) patient iPS cells with ATP synthase deficiency. Rapamycin treatment significantly improves the resistance of MILS neurons to glutamate toxicity. Surprisingly, in mitochondrially defective neurons, but not neuroprogenitor cells, ribosomal S6 and S6 kinase phosphorylation increased over time, despite activation of AMPK, which is often linked to mTOR inhibition. A rapamycin-induced decrease in protein synthesis, a major energy-consuming process, may account for its ATP-saving effect. We propose that a mild reduction in protein synthesis may have the potential to treat mitochondria-related neurodegeneration.

• Authors: Xinde Zheng, Leah Boyer, Mingji Jin, Yongsung Kim, Weiwei Fan, Cedric Bardy, Travis Berggren, Ronald M Evans, Fred H Gage, Tony Hunter
• Journal: eLife (Elife) Vol. 5 (03 23 2016) ISSN: 2050-084X [Electronic] England
• PMID: 27008180 (Publication Type: Journal Article)

Chemical References

• Neuroprotective Agents
• Adenosine Triphosphate
• MTOR protein, human
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Adenosine Triphosphate (metabolism)
• Cells, Cultured
• Humans
• Mitochondria (metabolism)
• Neurodegenerative Diseases (pathology)
• Neurons (drug effects, physiology)
• Neuroprotective Agents (metabolism)
• Protein Biosynthesis (drug effects)
• Sirolimus (metabolism)
• TOR Serine-Threonine Kinases (antagonists & inhibitors)